{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T12:44:34Z","timestamp":1782823474710,"version":"3.54.5"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03135-5","type":"journal-article","created":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T06:51:37Z","timestamp":1741416697000},"page":"2168-2189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-1943","authenticated-orcid":false,"given":"Hideaki","family":"Kaneto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-9574","authenticated-orcid":false,"given":"Yoko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-3697","authenticated-orcid":false,"given":"Yasuo","family":"Terauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"3135_CR1","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577\u201389.","journal-title":"N Engl J Med"},{"key":"3135_CR2","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1111\/jdi.13306","volume":"11","author":"E Araki","year":"2020","unstructured":"Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. J Diabetes Investig. 2020;11:1020\u201376.","journal-title":"J Diabetes Investig"},{"key":"3135_CR3","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/ggi.12986","volume":"16","author":"Japan Diabetes Society","year":"2016","unstructured":"Japan Diabetes Society. Japan Geriatrics Society Joint Committee on improving care for elderly patients with diabetes: glycemic targets for elderly patients with diabetes. Geriatr Gerontol Int. 2016;16:1243\u20135.","journal-title":"Geriatr Gerontol Int"},{"key":"3135_CR4","unstructured":"Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2019. 2020. https:\/\/www.pmda.go.jp\/files\/000267880.pdf. Accessed Mar 21 2024."},{"key":"3135_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/03007995.2018.1541790","volume":"35","author":"L Blonde","year":"2019","unstructured":"Blonde L, Anderson JE, Chava P, Dendy JA. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr Med Res Opin. 2019;35:793\u2013804.","journal-title":"Curr Med Res Opin"},{"key":"3135_CR6","unstructured":"Sanofi. Half-year financial report: 2020 edition. 2020. Accessed 07 October 2024."},{"issue":"Suppl 4","key":"3135_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.14005","volume":"22","author":"H Kaneto","year":"2020","unstructured":"Kaneto H, Takami A, Spranger R, et al. Efficacy and safety of insulin glargine\/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: the LixiLan JP-L randomized clinical trial. Diabetes Obes Metab. 2020;22(Suppl 4):3\u201313.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 4","key":"3135_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/dom.14036","volume":"22","author":"Y Terauchi","year":"2020","unstructured":"Terauchi Y, Nakama T, Spranger R, et al. Efficacy and safety of insulin glargine\/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: a randomized, 26-week, open-label, multicentre study: the LixiLan JP-O2 randomized clinical trial. Diabetes Obes Metab. 2020;22(Suppl 4):14\u201323.","journal-title":"Diabetes Obes Metab"},{"key":"3135_CR9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/dc19-2452","volume":"43","author":"H Watada","year":"2020","unstructured":"Watada H, Takami A, Spranger R, et al. Efficacy and safety of 1:1 fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide in Japanese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: the LixiLan JP-O1 randomized clinical trial. Diabetes Care. 2020;43:1249\u201357.","journal-title":"Diabetes Care"},{"key":"3135_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s13300-022-01333-w","volume":"14","author":"M Matsuhisa","year":"2023","unstructured":"Matsuhisa M, Miyoshi H, Yabe D, et al. Use of iGlarLixi for management of type 2 diabetes in Japanese clinical practice: SPARTA Japan, a retrospective observational study. Diabetes Ther. 2023;14:219\u201336.","journal-title":"Diabetes Ther"},{"key":"3135_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03050-1(Accessed2024\/11\/21)","author":"S Mizuno","year":"2024","unstructured":"Mizuno S, Minatoya M, Osaga S, Chin R, Imori M. Investigation of severe hypoglycemia risk among patients with diabetes treated with ultra-rapid lispro in Japan. Adv Ther. 2024. https:\/\/doi.org\/10.1007\/s12325-024-03050-1(Accessed2024\/11\/21).","journal-title":"Adv Ther"},{"key":"3135_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s13300-023-01373-w","volume":"14","author":"H Miyoshi","year":"2023","unstructured":"Miyoshi H, Matsuhisa M, Yabe D, et al. Use of iGlarLixi for the management of type 2 diabetes in Japanese clinical practice: prior treatment subgroup analysis of the SPARTA Japan study. Diabetes Ther. 2023;14:671\u201389.","journal-title":"Diabetes Ther"},{"key":"3135_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108647","volume":"172","author":"T Hirose","year":"2021","unstructured":"Hirose T, Odawara M, Matsuhisa M, et al. Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U\/mL: a subgroup analysis of 12-month post-marketing surveillance study (X-STAR study). Diabetes Res Clin Pract. 2021;172: 108647.","journal-title":"Diabetes Res Clin Pract"},{"key":"3135_CR14","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1080\/14656566.2020.1785430","volume":"21","author":"M Odawara","year":"2020","unstructured":"Odawara M, Matsuhisa M, Hirose T, et al. Effectiveness and safety of insulin glargine 300 unit\/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study). Expert Opin Pharmacother. 2020;21:1771\u201380.","journal-title":"Expert Opin Pharmacother"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03135-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03135-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T06:50:56Z","timestamp":1744872656000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03135-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3135"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03135-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hideaki Kaneto has received lecture fees from Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Sanofi K.K., Novo Nordisk Pharma Ltd., Sumitomo Pharma Co., Ltd., Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Astellas Pharma Inc. and AstraZeneca K.K.; research expenses or grants from Taisho Pharmaceutical Co., Ltd., Summit Pharma Co., Ltd. and Nippon Boehringer Ingelheim Co., Ltd.; scholarship (incentive) donations, etc. from Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Sanofi K.K., Novo Nordisk Pharma Ltd., Sumitomo Pharma Co., Ltd., Daiichi Sankyo Company, Mitsubishi Tanabe Pharma Corporation, Kowa Company, Ltd., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Astellas Pharma Inc. and Abbott Japan LLC. Yasuo Terauchi has received lecture fees from MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K., Sanofi K.K., Sumitomo Pharma Co., Ltd., AstraZeneca K.K., Astellas Pharma Inc., and Kowa Company, Ltd.; and scholarship (incentive) donations, etc. from Nippon Boehringer Ingelheim Co., Ltd. and Sumitomo Pharma Co., Ltd. Makiko Hatanaka, Yukiko Morimoto and Yoko Takahashi are employees of Sanofi K.K. Makiko Hatanaka is a shareholder of Sanofi K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the Japanese Ministerial Ordinance on Good Post-Marketing Study Practice (Ministry of Health, Labour and Welfare Ordinance No. 171, December 20, 2004) and the ethical guidelines for medical and health research involving human subjects. Under these Japanese regulations, this study was conducted without the review or approval by the ethics committee of the participating medical institutions. All data were collected from the MDV database; the authors had no access to individuals\u2019 medical records.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}